Investors Buy High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 37,691 put options on the stock. This represents an increase of 38% compared to the typical volume of 27,275 put options.

Wall Street Analyst Weigh In

TEVA has been the topic of several research reports. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares during the last quarter. DGS Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares during the last quarter. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after purchasing an additional 1,094 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.12 during trading hours on Monday, reaching $22.21. 7,436,313 shares of the company’s stock were exchanged, compared to its average volume of 9,438,637. The company has a 50-day moving average of $17.79 and a 200 day moving average of $17.52. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The firm has a market capitalization of $25.16 billion, a price-to-earnings ratio of -26.13, a P/E/G ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a 1-year low of $10.34 and a 1-year high of $22.25.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.